Therapeutic ISCOMATRIX (TM) adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Adele M Barr, Anabel Silva, Sandro Prato, Gabrielle T Belz, Eugene Maraskovsky, Adriana Baz Morelli
Cancer Immunology, Immunotherapy | SPRINGER | Published : 2020
Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic-polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prosta..View full abstract
Awarded by National Health and Medical Research Council Fellowship
Awarded by National Health and Medical Research Council (NHMRC) of Australia
At the time of completing this work, Adele Barr was the recipient of National Health and Medical Research Council Fellowship CDA APP1006663. Gabrielle T. Belz is supported by a fellowship from the National Health and Medical Research Council (NHMRC) of Australia (APP1135898).